Suchergebnisse - "Multicenter Study"

PubPharm (3.805)

1

Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective : A multicenter study

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2019

von Sgarbura, O. | Hübner, M. | Alyami, M. | +6

2

Cancer-related fatigue and self-care agency : A multicentre survey of patients receiving chemotherapy

enthalten in: Journal of clinical nursing | 2019

von O'Regan, P. | McCarthy, G. | O'Reilly, S. | +4

3

Metronomic chemotherapy for advanced breast cancer patients in the real world practice : Final results of the VICTOR-6 study

enthalten in: Breast (Edinburgh, Scotland) | 2019

von Cazzaniga, M. | Pinotti, G. | Montagna, E. | +69

4

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas : a multicenter retrospective analysis

enthalten in: Scientific reports | 2019

von Hong, J. | Yoon, D. | Yoon, S. | +15

5

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

enthalten in: Prostate cancer and prostatic diseases | 2019

von Nickols, N. | Nazarian, R. | Zhao, S. | +28

6

A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia

enthalten in: Investigational new drugs | 2019

von Capriotti, K. | Anadkat, M. | Choi, J. | +6

7

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

enthalten in: Investigational new drugs | 2019

von Park, I. | Lee, H. | Bae, W. | +2

8

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

enthalten in: International journal of clinical oncology | 2019

von Tsuchiya, T. | Imanaka, K. | Iwaki, Y. | +4

9

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

enthalten in: Investigational new drugs | 2019

von Nishio, M. | Murakami, H. | Ohe, Y. | +11

10

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

enthalten in: Leukemia & lymphoma | 2019

von Foltz, L. | Pica, G. | Zerazhi, H. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[381]